Baxter International (NYSE:BAX) Given New $19.00 Price Target at Citigroup

Baxter International (NYSE:BAX) had its target price decreased by stock analysts at Citigroup from $21.00 to $19.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “neutral” rating on the medical instruments supplier’s stock. Citigroup’s price target suggests a potential upside of 5.38% from the company’s previous close.

Other equities research analysts also recently issued research reports about the stock. Jefferies Financial Group lowered their price objective on shares of Baxter International from $21.00 to $19.00 and set a “hold” rating for the company in a research report on Friday, February 13th. Morgan Stanley decreased their target price on Baxter International from $19.00 to $15.00 and set an “underweight” rating for the company in a research note on Tuesday, December 2nd. Wells Fargo & Company lowered their target price on Baxter International from $21.00 to $19.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. Wall Street Zen cut Baxter International from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, Zacks Research raised Baxter International from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Two analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $19.90.

Baxter International Stock Performance

BAX traded up $0.57 during trading hours on Wednesday, hitting $18.03. 3,642,869 shares of the stock were exchanged, compared to its average volume of 10,121,023. The stock has a market cap of $9.28 billion, a price-to-earnings ratio of -9.74, a price-to-earnings-growth ratio of 1.25 and a beta of 0.58. The stock has a 50-day simple moving average of $20.10 and a 200-day simple moving average of $20.73. The company has a debt-to-equity ratio of 1.55, a current ratio of 2.31 and a quick ratio of 1.56. Baxter International has a 12 month low of $17.00 and a 12 month high of $35.77.

Baxter International (NYSE:BAX) last released its earnings results on Thursday, February 12th. The medical instruments supplier reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.53 by ($0.09). The business had revenue of $2.97 billion for the quarter, compared to the consensus estimate of $2.82 billion. Baxter International had a negative net margin of 8.51% and a positive return on equity of 16.95%. The firm’s revenue for the quarter was up 8.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.58 EPS. Baxter International has set its FY 2026 guidance at 1.850-2.050 EPS. Analysts anticipate that Baxter International will post 2.48 earnings per share for the current year.

Institutional Trading of Baxter International

Large investors have recently added to or reduced their stakes in the business. Basepoint Wealth LLC acquired a new position in Baxter International during the 4th quarter worth $26,000. CoreFirst Bank & Trust bought a new stake in shares of Baxter International during the second quarter valued at about $27,000. Imprint Wealth LLC bought a new stake in shares of Baxter International during the third quarter valued at about $27,000. MTM Investment Management LLC acquired a new stake in Baxter International in the second quarter worth about $30,000. Finally, CYBER HORNET ETFs LLC bought a new position in Baxter International in the 2nd quarter valued at about $40,000. 90.19% of the stock is currently owned by institutional investors and hedge funds.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.